Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP InvestigatesAccesswire • 03/06/24
Alnylam Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Alnylam (ALNY)Accesswire • 03/05/24
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesBusiness Wire • 03/05/24
Levi & Korsinsky Reminds Shareholders of an Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Regarding Potential Securities Fraud AllegationsAccesswire • 03/03/24
ALNY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Shareholders Who Lost MoneyAccesswire • 02/21/24
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityBusiness Wire • 02/15/24
Gear Up for Alnylam (ALNY) Q4 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 02/12/24
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 01/29/24
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen's AssociationBusiness Wire • 01/09/24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional UpdatesBusiness Wire • 01/07/24
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/02/24
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayBusiness Wire • 12/13/23